<DOC>
	<DOCNO>NCT01951586</DOCNO>
	<brief_summary>This randomized phase 2 trial study effect add denosumab standard chemotherapy treatment advance lung cancer .</brief_summary>
	<brief_title>Denosumab Combination With Chemotherapy First-line Treatment Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This global phase 2 randomize double-blind placebo-controlled study subject Stage IV untreated NSCLC without bone metastasis . Eligible subject receive 4 6 cycle standard care platinum-doublet chemotherapy regimen . Approximately 216 subject randomize 2:1 ratio receive denosumab match placebo first investigational product dose coincide subject 's first cycle chemotherapy continue primary analysis , unacceptable toxicity , withdrawal consent , death , lose follow-up . Subjects offer open label denosumab study result show positive benefit : risk profile , follow long-term , 2 year . All subject receive daily dietary supplement least 500 mg calcium 400 IU vitamin D .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Histologically cytologically confirm stage IV nonsmall cell lung carcinoma ( NSCLC ) , accord 7th TNM classification ( cytological specimen obtain bronchial wash brushing , fineneedle aspiration acceptable ) Subject available provide consent release sponsor ( designee ) tumor block confirm tumor content ( approximately 20 unstained charge slide [ minimum 7 slide mandatory ] ) correspond pathology report Planned receive 4 6 cycle pemetrexed gemcitabine combination cisplatin carboplatin â€¢ For subject receive pemetrexed , plan receive vitamin B12 folate per pemetrexed approve label Radiographically evaluable ( measurable nonmeasurable ) disease ( accord modify RECIST 1.1 criterion Other inclusion criterion may apply Known presence document sensitize epidermal growth factor receptor ( EGFR ) activate mutation EML4ALK translocation ( screen follow local standard , strongly encourage nonsquamous histology ) Known brain metastasis ( systematic screening patient mandatory ) Any prior systemic therapy ( randomisation ) treatment NSCLC ( include chemoradiation ) , except nonmetastatic disease complete least 6 month prior randomization Planned receive bevacizumab Significant dental/oral disease , include prior history current evidence osteonecrosis/ osteomyelitis jaw , follow : Active dental jaw condition require oral surgery Nonhealed dental/oral surgery Planned invasive dental procedure course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>